-
1Academic Journal
Συγγραφείς: Borodavina E.V., Shurinov A.Y., Krylov V.V.
Πηγή: Head and Neck Tumors; Vol 15, No 1 (2025); 40-46 ; Опухоли головы и шеи; Vol 15, No 1 (2025); 40-46 ; 2411-4634 ; 2222-1468
Θεματικοί όροι: progressive metastatic radioiodine refractory differentiated thyroid cancer, progression, thyroglobulin, Response evaluation criteria in solid tumors, targeted therapy, lenvatinib, response to treatment, прогрессирующий метастатический радиойодрефрактерный дифференцированный рак щитовидной железы, прогрессирование, тиреоглобулин, критерии оценки ответа солидных опухолей, таргетная терапия, ленватиниб, ответ на лечение
Περιγραφή αρχείου: application/pdf
Relation: https://ogsh.abvpress.ru/jour/article/view/1041/659; https://ogsh.abvpress.ru/jour/article/view/1041
-
2Academic Journal
Συγγραφείς: E. V. Borodavina, S. I. Kutukova, A. Yu. Shurinov, V. V. Krylov, Е. В. Бородавина, С. И. Кутукова, А. Ю. Шуринов, В. В. Крылов
Συνεισφορές: The work was prepared with the financial support of the Eisai company., Работа подготовлена при финансовой поддержке ООО «Эйсай».
Πηγή: Head and Neck Tumors (HNT); Том 14, № 4 (2024); 42-50 ; Опухоли головы и шеи; Том 14, № 4 (2024); 42-50 ; 2411-4634 ; 2222-1468
Θεματικοί όροι: терапевтические каникулы, radioiodine-refractory differentiated thyroid cancer, adverse events, progression-free survival, overall survival, drug holidays, радиойодрефрактерный дифференцированный рак щитовидной железы, нежелательные явления, выживаемость без прогрессирования, общая выживаемость
Περιγραφή αρχείου: application/pdf
Relation: https://ogsh.abvpress.ru/jour/article/view/1023/650; Pacini F., Ito Y., Luster M. et al. Radioactive iodine-refractory differentiated thyroid cancer: Unmet needs and future directions. Exp Rev Endocrinol Metab 2012;7(5):541–54. DOI:10.1586/eem.12.36; Xing M., Haugen B.R., Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013;381(9871):1058–69. DOI:10.1016/S0140-6736(13)60109-9; Cabanillas M.E., Takahashi S. Лечение нежелательных явлений, ассоциированных с приемом ленватиниба, у пациентов с радиойодрефрактерным дифференцированным раком щитовидной железы. Опухоли головы и шеи 2019;9(4):49–61. DOI:10.17650/2222-1468-2019-9-4-49-61; Durante C., Haddy N., Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91(8):2892–9. DOI:10.1210/jc.2005-2838; Schlumberger M., Tahara M., Wirth L.J. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372(7):621–30. DOI:10.1056/NEJMoa1406470; Gianoukakis A.G., Dutcus C.E., Batty N. et al. Prolonged duration of response in lenvatinib responders with thyroid cancer. Endocr Relat Cancer 2018;25(6):699–704. DOI:10.1530/ERC-18-0049; Бородавина Е.В., Исаев П.А., Шуринов А.Ю. и др. Эффективность и переносимость ленватиниба при радиойодрезистентном дифференцированном раке щитовидной железы по результатам многоцентрового наблюдательного исследования в Российской Федерации. Опухоли головы и шеи 2020;10(1):65–72. DOI:10.17650/2222-1468-2020-10-1-65-72; Locati L.D., Piovesan A., Durante C. et al. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. Eur J Cancer 2019;118:35–40. DOI:10.1016/j.ejca.2019.05.031; Takahashi S., Tahara M., Ito K. et al. Safety and effectiveness of lenvatinib in 594 patients with unresectable thyroid cancer in an all-case post-marketing observational study in Japan. Adv Ther 2020;37(9):3850–62. DOI:10.1007/s12325-020-01433-8; Kish J.K., Chatterjee D., Wan Y. et al. Lenvatinib and subsequent therapy for radioactive iodine-refractory differentiated thyroid cancer: a real-world study of clinical effectiveness in the United States. Adv Ther 2020;37(6):2841–52. DOI:10.1007/s12325-020-01362-6; Song E., Kim M., Kim E.Y. et al. Lenvatinib for radioactive iodine-refractory differentiated thyroid carcinoma and candidate biomarkers associated with survival: a multicenter study in Korea. Thyroid 2020;30(5):732–8. DOI:10.1089/thy.2019.0476; Румянцев П.О., Бородавина Е.В., Кутукова С.И., Васильева Е.Б. Персонализированная терапия ленватинибом прогрессирующего радиойодрефрактерного дифференцированного рака щитовидной железы в реальной клинической практике. Опухоли головы и шеи 2021;11(3):47–55. DOI:10.17650/2222-1468-2021-11-3-47-55; Matsuyama C., Enokida T., Ueda Y. et al. Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study. Front Oncol 2023;13:1139659. DOI:10.3389/fonc.2023.1139659; Tahara M., Takami H., Ito Y. et al. A prospective cohort study exploring the effect of lenvatinib planned drug holidays in treatment of differentiated thyroid cancer. Thyroid 2024;34(5):566–74. DOI:10.1089/thy.2023.0553; Mikoshiba T., Sekimizu M., Kono T. et al. Utility and optimal management of planned drug holidays during lenvatinib treatment in patients with unresectable differentiated thyroid cancer: a real-world multi-center study. Endocrine 2024;85(2):777–85. DOI:10.1007/s12020-024-03744-0; Felicetti F., Nervo A., Piovesan A. et al. Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer. Expert Rev Anticancer Ther 2017;17(12):1093–8. DOI:10.1080/14737140.2017.1390432; Marotta V., Colao A., Faggiano A. Complete disappearance of liver metastases in a patient with iodine-refractory differentiated thyroid cancer subjected to sorafenib re-challenge. Endocrine 2015;50(3):824–5. DOI:10.1007/s12020-015-0570-5; Takinami M., Yokota T. Rechallenge with lenvatinib after refractoriness to initial lenvatinib followed by sorafenib in a patient with metastatic papillary thyroid carcinoma. Case Rep Oncol 2020;13(2):522–7. DOI:10.1159/000507344; Yokota T., Hamauchi S., Kawakami T., Fushiki K. Lenvatinib rechallenge after failure of lenvatinib and sorafenib in metastatic thyroid cancer. Invest New Drugs 2024;42(4):361–8. DOI:10.1007/s10637-024-01449-9; Guo R., Chen X., Wang T. et al. Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer. BMC Cancer 2011;11:90. DOI:10.1186/1471-2407-11-90; Becker A., Crombag L., Heideman D.A. et al. Retreatment with erlotinib: regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Eur J Cancer 2011;47(17):2603–6. DOI:10.1016/j.ejca.2011.06.046; Brose M.S., Panaseykin Y., Konda B. et al. A randomized study of lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid Cancer. J Clin Endocrinol Metab 2022;107(3):776–87. DOI:10.1210/clinem/dgab731; Yu J., Liu Z., Su Y. et al. Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 2024;100(4):379–88. DOI:10.1111/cen.15027; https://ogsh.abvpress.ru/jour/article/view/1023
-
3Academic Journal
Συγγραφείς: M. S. Brose, Yu. Panaseykin, B. Konda, C. De la Fouchardiere, B. G.M. Hughes, A. G. Gianoukakis, Y. J. Park, I. Romanov, M. K. Krzyzanowska, S. Leboulleux, T. A. Binder, C. Dutcus, R. Xie, M. H. Taylor
Πηγή: Опухоли головы и шеи, Vol 12, Iss 1, Pp 86-98 (2022)
Θεματικοί όροι: 03 medical and health sciences, ленватиниб, 0302 clinical medicine, стартовая доза, ингибитор тирозинкиназ, радиойодрефрактерный дифференцированный рак щитовидной железы, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Σύνδεσμος πρόσβασης: https://doaj.org/article/d7a35ee1dee346c98829477eec0b69b8
-
4Academic Journal
Συγγραφείς: A. G. Gianoukakis, C. E. Dutcus, N. Batty, M. Guo, M. Baig
Συνεισφορές: Oxford PharmaGenesis Inc., Ньютаун, Пенсильвания, США, Inc., Woodcliff Lake, Нью-Джерси, США.
Πηγή: Head and Neck Tumors (HNT); Том 8, № 3 (2018); 53-60 ; Опухоли головы и шеи; Том 8, № 3 (2018); 53-60 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2018-8-3
Θεματικοί όροι: исследование SELECT, radioiodine-refractory differentiated thyroid carcinoma, duration of response, SELECT, радиойодрефрактерный дифференцированный рак щитовидной железы, длительность ответа
Περιγραφή αρχείου: application/pdf
Relation: https://ogsh.abvpress.ru/jour/article/view/361/343; Brose M. S., Nutting C. M., Jarzab B. et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384(9940):319–28. DOI:10.1016/S0140-6736(14)60421-9. PMID: 24768112.; Busaidy N. L., Cabanillas M. E. Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease. J Thyroid Res 2012;2012:618985.DOI:10.1155/2012/618985. PMID: 22530159.; Cooper D. S., Doherty G. M., Haugen B. R. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19(11):1167–214. DOI:10.1089/thy.2009.0110. PMID: 19860577.; Dieci M. V., Arnedos M., Andre F., Soria J. C. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov 2013;3(3):264–79. DOI:10.1158/2159-8290.CD-12-0362. PMID: 23418312.; Durante C., Haddy N., Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91(8):2892–9. DOI:10.1210/jc.2005-2838. PMID: 16684830.; Haddad R. I., Schlumberger M., Wirth L. J. et al. Incidence and timing of common adverse events in Lenvatinib treated patients from the SELECT trial and their association with survival outcomes. Endocrine 2017;56(1):121–8. DOI:10.1007/s12020‑017‑1233‑5. PMID: 28155175.; Laursen R., Wehland M., Kopp S. et al. Effects and role of multikinase inhibitors in thyroid cancer. Curr Pharm Des 2016;22(39):5915–26. DOI:10.2174/1381612822666160614084943. PMID: 27306093.; Matsui J., Funahashi Y., Uenaka T. et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008;14(17):5459–65. DOI:10.1158/1078-0432.CCR-07-5270. PMID: 18765537.; Matsui J., Yamamoto Y., Funahashi Y. et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 2008;122(3):664–71. DOI:10.1002/ijc.23131. PMID: 17943726.; Okamoto K., Kodama K., Takase K. et al. Antitumor activities of the targeted multityrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett 2013;340(1):97–103. DOI:10.1016/j.canlet. 2013.07.007. PMID: 23856031.; Pacini F., Ito Y., Luster M. et al. Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions. Exp Rev Endocrinol Metab 2012;7:541–54. DOI:10.1586/eem.12.36.; Pitoia F., Jerkovich F. Selective use of sorafenib in the treatment of thyroid cancer. Drug Des Devel Ther 2016;10: 1119–31. DOI:10.2147/DDDT.S82972. PMID: 27042004.; Schlumberger M., Tahara M., Wirth L. J. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372(7):621–30. DOI:10.1056/NEJMoa1406470. PMID: 25671254.; St Bernard R., Zheng L., Liu W. et al. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 2005;146(3):1145–53. DOI:10.1210/en.2004-1134. PMID: 15564323.; Tohyama O., Matsui J., Kodama K. et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014;2014:638747. DOI:10.1155/2014/638747. PMID: 25295214.; Worden F. Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer. Ther Adv Med Oncol 2014;6(6):267–79. DOI:10.1177/1758834014548188. PMID: 25364392.; Xing M., Haugen B. R., Schlumberger M. Progress in molecularbased management of differentiated thyroid cancer. Lancet 2013;381(9871):1058–69. DOI:10.1016/S0140-6736(13)60109-9. PMID: 23668556.; Yamamoto Y., Matsui J., Matsushima T. et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell 2014;6:18. DOI:10.1186/2045-824X-6-18. PMID: 25197551.; https://ogsh.abvpress.ru/jour/article/view/361